CS274504B2 - Preparation of enzymatic compounds for cholesterol optical indication - Google Patents
Preparation of enzymatic compounds for cholesterol optical indication Download PDFInfo
- Publication number
- CS274504B2 CS274504B2 CS503989A CS503989A CS274504B2 CS 274504 B2 CS274504 B2 CS 274504B2 CS 503989 A CS503989 A CS 503989A CS 503989 A CS503989 A CS 503989A CS 274504 B2 CS274504 B2 CS 274504B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- cholesterol
- group
- agent
- solution
- compounds
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 120
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 57
- 150000001875 compounds Chemical class 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 230000002255 enzymatic effect Effects 0.000 title claims description 7
- 230000003287 optical effect Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 32
- 238000001514 detection method Methods 0.000 claims abstract description 30
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 23
- 102000004190 Enzymes Human genes 0.000 claims abstract description 19
- 108090000790 Enzymes Proteins 0.000 claims abstract description 19
- 230000000007 visual effect Effects 0.000 claims abstract description 15
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 11
- 238000012800 visualization Methods 0.000 claims abstract description 11
- 231100000654 protein toxin Toxicity 0.000 claims abstract description 4
- 108700012359 toxins Proteins 0.000 claims abstract description 4
- 150000007949 saponins Chemical class 0.000 claims abstract description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 28
- 229940088598 enzyme Drugs 0.000 claims description 18
- -1 cicubasaponin Natural products 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 11
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 9
- 230000001588 bifunctional effect Effects 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 102000003992 Peroxidases Human genes 0.000 claims description 7
- 229930182470 glycoside Natural products 0.000 claims description 7
- 150000002338 glycosides Chemical class 0.000 claims description 7
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 7
- 150000001540 azides Chemical class 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- 125000000524 functional group Chemical group 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- MCLXKFUCPVGZEN-UHFFFAOYSA-N 4,6-dichloro-1,3,5-triazin-2-amine Chemical compound NC1=NC(Cl)=NC(Cl)=N1 MCLXKFUCPVGZEN-UHFFFAOYSA-N 0.000 claims description 5
- 102100033639 Acetylcholinesterase Human genes 0.000 claims description 5
- 108010022752 Acetylcholinesterase Proteins 0.000 claims description 5
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 5
- 102000003425 Tyrosinase Human genes 0.000 claims description 5
- 108060008724 Tyrosinase Proteins 0.000 claims description 5
- 229940022698 acetylcholinesterase Drugs 0.000 claims description 5
- 150000001299 aldehydes Chemical class 0.000 claims description 5
- 150000008064 anhydrides Chemical class 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 239000012948 isocyanate Substances 0.000 claims description 5
- 150000002513 isocyanates Chemical class 0.000 claims description 5
- 229920001059 synthetic polymer Polymers 0.000 claims description 5
- 102100031126 6-phosphogluconolactonase Human genes 0.000 claims description 4
- 108010029731 6-phosphogluconolactonase Proteins 0.000 claims description 4
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 claims description 4
- 102000002464 Galactosidases Human genes 0.000 claims description 4
- 108010093031 Galactosidases Proteins 0.000 claims description 4
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 claims description 4
- 108090001030 Lipoproteins Proteins 0.000 claims description 4
- 102000004895 Lipoproteins Human genes 0.000 claims description 4
- 102000009609 Pyrophosphatases Human genes 0.000 claims description 4
- 108010009413 Pyrophosphatases Proteins 0.000 claims description 4
- BWPGKXYWPBQBPV-MWQJAWBESA-N Theasaponin Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)CO1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)CO1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(C[C@H]14)(C)C)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BWPGKXYWPBQBPV-MWQJAWBESA-N 0.000 claims description 4
- BWPGKXYWPBQBPV-ZOADXXHESA-N Theasaponin Natural products O=C(O[C@@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@@H]7[C@H](O[C@@H]8[C@@H](O)[C@H](O)[C@H](O)CO8)[C@H](O)[C@@H](O)CO7)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O7)[C@H](O)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C BWPGKXYWPBQBPV-ZOADXXHESA-N 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 claims description 4
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 239000003228 hemolysin Substances 0.000 claims description 4
- 229930191040 juncoside Natural products 0.000 claims description 4
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- JNTJNUDLVQQYGM-NRZIZFFHSA-N tomatonin Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC4C(C3(CC[C@@H]2C1(C)CC1)C)[C@@H]([C@]2(OCC(C)CC2)O4)C)C1OC(C(C1O)O)OC(CO)C1OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O JNTJNUDLVQQYGM-NRZIZFFHSA-N 0.000 claims description 4
- ADHFZEPOBOTKSO-QLTVFDSQSA-N (1R,2S,4R,5'R,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-3-ol Chemical class O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 ADHFZEPOBOTKSO-QLTVFDSQSA-N 0.000 claims description 3
- HDXIQHTUNGFJIC-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-->2)-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HDXIQHTUNGFJIC-UHFFFAOYSA-N 0.000 claims description 3
- VNONINPVFQTJOC-RXEYMUOJSA-N Collettiside III Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VNONINPVFQTJOC-RXEYMUOJSA-N 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- DLUTTXMPJCVUFR-HJCIYZGTSA-N Parillin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@@H]1C[C@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@@H](C)CC1)O5)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DLUTTXMPJCVUFR-HJCIYZGTSA-N 0.000 claims description 3
- VNONINPVFQTJOC-ZGXDEBHDSA-N dioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O VNONINPVFQTJOC-ZGXDEBHDSA-N 0.000 claims description 3
- CJNUQCDDINHHHD-APRUHSSNSA-N dioscin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O CJNUQCDDINHHHD-APRUHSSNSA-N 0.000 claims description 3
- 150000002605 large molecules Chemical class 0.000 claims description 3
- 150000002772 monosaccharides Chemical class 0.000 claims description 3
- VQOXZBDYSJBXMA-RKEBNKJGSA-N nystatin a1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@@H]1OC1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)CC(O)CC(O)CC(O)CCC(O)C(O)C[C@](O)(CC(O)C2C(O)=O)OC2C1 VQOXZBDYSJBXMA-RKEBNKJGSA-N 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- DLUTTXMPJCVUFR-UHFFFAOYSA-N parillin Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CCC4CC5OC(C(C(O)C1OC2C(C(O)C(O)C(C)O2)O)OC2C(C(O)C(O)C(CO)O2)O)OC1COC1OC(CO)C(O)C(O)C1O DLUTTXMPJCVUFR-UHFFFAOYSA-N 0.000 claims description 3
- VNONINPVFQTJOC-UHFFFAOYSA-N polyphyllin III Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O VNONINPVFQTJOC-UHFFFAOYSA-N 0.000 claims description 3
- WXMARHKAXWRNDM-UHFFFAOYSA-N (25R)-5alpha-spirost-5-en-3beta-ol 3-O-beta-D-galactopyranoside Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1O WXMARHKAXWRNDM-UHFFFAOYSA-N 0.000 claims description 2
- YQEMAEKYNNOCBY-UHFFFAOYSA-N (25R)-diosgenin-3-O-beta-D-glucopyranosyl(1-3)-[alpha-L-rhamnopyranosyl(1-2)]-beta-D-glucopyranoside Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C1OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O YQEMAEKYNNOCBY-UHFFFAOYSA-N 0.000 claims description 2
- JPEQATLMKATGAQ-UHFFFAOYSA-N 13,28-epoxy-3beta-[O2-beta-D-glucopyranosyl-O4-(O3-beta-D-glucopyranosyl-O2-beta-D-xylopyranosyl-beta-D-glucopyranosyl)-alpha-L-arabinopyranosyloxy]-16alpha-hydroxy-oleanan-30-al Natural products C12CC(C)(C=O)CCC2(C(CC2(C)C3(C)CCC4C5(C)C)O)COC21CCC3C4(C)CCC5OC(C(C1O)OC2C(C(O)C(O)C(CO)O2)O)OCC1OC(C1OC2C(C(O)C(O)CO2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O JPEQATLMKATGAQ-UHFFFAOYSA-N 0.000 claims description 2
- KTFHPQODYKNDKE-UHFFFAOYSA-N 16'-[(5-{[3,4-dihydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl)oxy]-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-10'-one Chemical compound O1C2(OCC(C)CC2)C(C)C(C2(C(=O)CC3C4(C)CC5)C)C1CC2C3CCC4CC5OC(C(C1O)O)OC(CO)C1OC(C(C1O)O)OC(CO)C1OC1OC(CO)C(O)C(O)C1O KTFHPQODYKNDKE-UHFFFAOYSA-N 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- ZXWQZGROTQMXME-KMPXOGLXSA-N 2-hydroxy-n-[(e)-3-hydroxy-1-[(3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]tetracosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)\C=C\CCCCCCCCCCCCC)COC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O ZXWQZGROTQMXME-KMPXOGLXSA-N 0.000 claims description 2
- 241000242758 Actinia Species 0.000 claims description 2
- AXNVHPCVMSNXNP-GKTCLTPXSA-N Aescin Natural products O=C(O[C@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@H]7[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C AXNVHPCVMSNXNP-GKTCLTPXSA-N 0.000 claims description 2
- NVCUAFIUMZCPGV-XJOCBOPTSA-N Agavoside A Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)(C(=O)C3)[C@H]3[C@H](C)[C@@]5(O[C@H]3C4)OC[C@@H](C)CC5)CC2)CC1 NVCUAFIUMZCPGV-XJOCBOPTSA-N 0.000 claims description 2
- RROGHRHLBLVQSG-UUWFFIQNSA-N Akeboside Std Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(CO)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RROGHRHLBLVQSG-UUWFFIQNSA-N 0.000 claims description 2
- 229930190133 Alliumoside Natural products 0.000 claims description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 2
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 claims description 2
- 241000157855 Cinchona Species 0.000 claims description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 claims description 2
- JPEQATLMKATGAQ-JOONIPAFSA-N Cyclamin Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)CO1)O)O[C@H]1CO[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]45OC[C@]6([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)O)CC[C@](C[C@H]65)(C)C=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JPEQATLMKATGAQ-JOONIPAFSA-N 0.000 claims description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims description 2
- 102000018832 Cytochromes Human genes 0.000 claims description 2
- 108010052832 Cytochromes Proteins 0.000 claims description 2
- 101710112752 Cytotoxin Proteins 0.000 claims description 2
- WBGSZIZXDQCBHY-UHFFFAOYSA-N Desglucoparillin Natural products CC1CCC2(OC1)OC3CC4C5CCC6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(COC8OC(CO)C(OC9OC(C)C(O)C(O)C9O)C(O)C8O)C(O)C(O)C7O WBGSZIZXDQCBHY-UHFFFAOYSA-N 0.000 claims description 2
- 241000202567 Fatsia japonica Species 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- YQEMAEKYNNOCBY-IEMDQPGHSA-N Gracillin Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YQEMAEKYNNOCBY-IEMDQPGHSA-N 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 108700027766 Listeria monocytogenes hlyA Proteins 0.000 claims description 2
- NKMDIWKRKQFYPH-UHFFFAOYSA-N Lupan Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(C)C)C5C4CCC3C21C NKMDIWKRKQFYPH-UHFFFAOYSA-N 0.000 claims description 2
- 241000242770 Metridium senile Species 0.000 claims description 2
- 102000036675 Myoglobin Human genes 0.000 claims description 2
- 108010062374 Myoglobin Proteins 0.000 claims description 2
- 101710183389 Pneumolysin Proteins 0.000 claims description 2
- SUHZCFHVHYUSEP-UVSPAHOSSA-N Sarsaparilloside Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@@H]1C[C@H]2CC[C@H]3[C@@H]4C[C@@H]5O[C@]([C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)(O)CC[C@H](C)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SUHZCFHVHYUSEP-UVSPAHOSSA-N 0.000 claims description 2
- SUHZCFHVHYUSEP-UHFFFAOYSA-N Sarsaparilloside Natural products O1C(CO)C(O)C(O)C(O)C1OCC(C)CCC(C(C1C2(C)CCC3C4(C)CC5)C)(O)OC1CC2C3CCC4CC5OC(C(C(O)C1OC2C(C(O)C(O)C(C)O2)O)OC2C(C(O)C(O)C(CO)O2)O)OC1COC1OC(CO)C(O)C(O)C1O SUHZCFHVHYUSEP-UHFFFAOYSA-N 0.000 claims description 2
- GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 108010055297 Sterol Esterase Proteins 0.000 claims description 2
- 235000021536 Sugar beet Nutrition 0.000 claims description 2
- RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 claims description 2
- QERHBVOJJKVACB-NAURGQNWSA-N Tigonin Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O QERHBVOJJKVACB-NAURGQNWSA-N 0.000 claims description 2
- QERHBVOJJKVACB-BKZBNQMKSA-N Tigonin Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]2C[C@H]3[C@@](C)([C@@H]4[C@H]([C@H]5[C@@](C)([C@H]6[C@H](C)[C@@]7(O[C@H]6C5)OC[C@H](C)CC7)CC4)CC3)CC2)O[C@H]1CO)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@H](O)CO2)[C@H](O)[C@@H](CO)O1 QERHBVOJJKVACB-BKZBNQMKSA-N 0.000 claims description 2
- NVCUAFIUMZCPGV-RGIGLGGVSA-N agavoside A Chemical compound O([C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(C(=O)C[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O NVCUAFIUMZCPGV-RGIGLGGVSA-N 0.000 claims description 2
- 108010012597 alveolysin Proteins 0.000 claims description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 2
- 229960003942 amphotericin b Drugs 0.000 claims description 2
- RROGHRHLBLVQSG-UHFFFAOYSA-N calthoside D Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(CO)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O RROGHRHLBLVQSG-UHFFFAOYSA-N 0.000 claims description 2
- SXHVTFBSLPWMLD-UHFFFAOYSA-N cyclamin Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2CCC45OCC6(CCC(C)(CC46)C=O)C(O)CC35C)OC7OCC(OC8OC(CO)C(O)C(OOC9OC(CO)C(O)C(O)C9O)C8OC%10OCC(O)C(O)C%10O)C(O)C7OC%11OC(CO)C(O)C(O)C%11O SXHVTFBSLPWMLD-UHFFFAOYSA-N 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 239000002619 cytotoxin Substances 0.000 claims description 2
- UQXYFHWTJCVQDS-DBXQGTFUSA-N desglucodigitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CCC3[C@@]4(C)CC(O)C(CC4CCC3C2[C@@H]1O)[C@]1(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)CO1)O)C)[C@@H]1C)C11CC[C@@H](C)CO1 UQXYFHWTJCVQDS-DBXQGTFUSA-N 0.000 claims description 2
- KPQCBBBNEYDLKJ-ZOKXAGJGSA-N desglucodigitonin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3[C@@H](O)[C@H]4[C@@H]5CC[C@H]6C[C@@H](O[C@@H]7O[C@H](CO)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O[C@@H]9OC[C@@H](O)[C@H](O)[C@H]9O)[C@H]8O[C@@H]%10O[C@H](CO)[C@H](O)[C@H](O)[C@H]%10O)[C@H](O)[C@H]7O)[C@H](O)C[C@]6(C)[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C KPQCBBBNEYDLKJ-ZOKXAGJGSA-N 0.000 claims description 2
- UBMCTHWOOSUTHL-UHFFFAOYSA-N desglucoparillin Chemical compound O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CCC4CC5OC(C(C(O)C1OC2C(C(O)C(O)C(C)O2)O)O)OC1COC1OC(CO)C(O)C(O)C1O UBMCTHWOOSUTHL-UHFFFAOYSA-N 0.000 claims description 2
- WXMARHKAXWRNDM-GAMIEDRGSA-N diosgenin 3-O-beta-D-glucoside Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WXMARHKAXWRNDM-GAMIEDRGSA-N 0.000 claims description 2
- 229940012952 fibrinogen Drugs 0.000 claims description 2
- LDDIPQISQQULJN-DCXLXNQSSA-N gracillin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O LDDIPQISQQULJN-DCXLXNQSSA-N 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 229940072221 immunoglobulins Drugs 0.000 claims description 2
- ZQIOPEXWVBIZAV-ZKYCIREVSA-N lanostane Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C)[C@@H]1[C@@H]2[C@]2(C)CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 ZQIOPEXWVBIZAV-ZKYCIREVSA-N 0.000 claims description 2
- LHHAGBJPCRSFHH-UHFFFAOYSA-N lilioglycoside G Natural products CC1CCC2(OC1)OC3CC4C5CC=C6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(CO)C(O)C(OC8OC(CO)C(O)C(O)C8OC9OC(C)C(O)C(O)C9O)C7O LHHAGBJPCRSFHH-UHFFFAOYSA-N 0.000 claims description 2
- 210000003712 lysosome Anatomy 0.000 claims description 2
- 230000001868 lysosomic effect Effects 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 210000003470 mitochondria Anatomy 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 125000003410 quininyl group Chemical group 0.000 claims description 2
- IAGSHEHQJJTLLR-UHFFFAOYSA-N sapindoside B Natural products OC1C(C)OC(OC2C(OCC(O)C2O)OC2C(C3C(C4C(C5(CCC6(CCC(C)(C)CC6C5=CC4)C(O)=O)C)(C)CC3)(C)CC2)(C)CO)C(O)C1OC1OCC(O)C(O)C1O IAGSHEHQJJTLLR-UHFFFAOYSA-N 0.000 claims description 2
- 229930182490 saponin Natural products 0.000 claims description 2
- 235000017709 saponins Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 108010052441 tetanolysin Proteins 0.000 claims description 2
- 108010051457 Acid Phosphatase Proteins 0.000 claims 5
- 102000013563 Acid Phosphatase Human genes 0.000 claims 5
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 claims 4
- 229930195180 Agavoside Natural products 0.000 claims 4
- 150000001840 cholesterol esters Chemical class 0.000 claims 3
- 125000003700 epoxy group Chemical group 0.000 claims 2
- AULWDENWMBJIIQ-UHFFFAOYSA-N (25R)-2alpha-hydroxy-5alpha-spirostan-3beta-yl O-beta-D-galactopyranosyl-(1 2)-O-[beta-D-xylopyranosyl-(1 3)]-O-beta-D-glucopyranosyl-(1 4)-beta-D-galactopyranoside Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CCC4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O AULWDENWMBJIIQ-UHFFFAOYSA-N 0.000 claims 1
- KQSZHSKJNNXOTD-UHFFFAOYSA-N 101843-83-8 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C3C(OC4C(C(O)C(O)CO4)O)CC4C5(C)CC(O)C(C5(C)CCC54CC53CC2)C2(C)OC(CC2)C(C)(C)O)(C)C)OCC(O)C1O KQSZHSKJNNXOTD-UHFFFAOYSA-N 0.000 claims 1
- LZKGFGLOQNSMBS-UHFFFAOYSA-N 4,5,6-trichlorotriazine Chemical compound ClC1=NN=NC(Cl)=C1Cl LZKGFGLOQNSMBS-UHFFFAOYSA-N 0.000 claims 1
- 108010083590 Apoproteins Proteins 0.000 claims 1
- 102000006410 Apoproteins Human genes 0.000 claims 1
- ZJCKMLSMXPLTKX-UHFFFAOYSA-N Asparagoside C Chemical compound O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CCC4CC5OC(C1O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O ZJCKMLSMXPLTKX-UHFFFAOYSA-N 0.000 claims 1
- 108090000317 Chymotrypsin Proteins 0.000 claims 1
- 239000004971 Cross linker Substances 0.000 claims 1
- DVVXPGPLSDJWAW-UHFFFAOYSA-N F-gitonin Natural products CC1CCC2(OC1)OC3CC4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(OC9OCC(O)C(O)C9O)C(O)C8OC%10OC(CO)C(O)C(O)C%10O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C DVVXPGPLSDJWAW-UHFFFAOYSA-N 0.000 claims 1
- AULWDENWMBJIIQ-KFRXWHRXSA-N Gitonin Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)C[C@H]1O)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O AULWDENWMBJIIQ-KFRXWHRXSA-N 0.000 claims 1
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 claims 1
- 239000004366 Glucose oxidase Substances 0.000 claims 1
- 241000270295 Serpentes Species 0.000 claims 1
- 102000000019 Sterol Esterase Human genes 0.000 claims 1
- 108010011834 Streptolysins Proteins 0.000 claims 1
- MRJWZGUJYIXMEU-SLPGGIOYSA-N [(2r,3s,4s,5r)-1,3,4,5-tetrahydroxy-6-oxohexan-2-yl] dihydrogen phosphate Chemical compound OP(=O)(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C=O MRJWZGUJYIXMEU-SLPGGIOYSA-N 0.000 claims 1
- SKHJNNFXCKTDBG-UHFFFAOYSA-N ac1mqz13 Chemical compound O1C2(OCC(C)CC2)C(C)C(C2(CCC3C45C)C)C1CC2C3CC=C4CC(O)CC5OC1OCC(O)C(O)C1OC1OC(C)C(O)C(O)C1O SKHJNNFXCKTDBG-UHFFFAOYSA-N 0.000 claims 1
- UUFUBRZQDOOECH-UHFFFAOYSA-N agavasaponin h Chemical compound O1C(CO)C(O)C(O)C(O)C1OCC(C)CCC(C(C1C2(C)C(=O)CC3C4(C)CC5)C)(O)OC1CC2C3CCC4CC5OC(C(C1O)O)OC(CO)C1OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(C)O3)O)C(O)C(C)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O UUFUBRZQDOOECH-UHFFFAOYSA-N 0.000 claims 1
- SKHJNNFXCKTDBG-NACOJTGESA-N alliospiroside A Natural products C[C@H]1CC[C@@]2(OC1)O[C@@H]3C[C@H]4[C@H]5CC=C6C[C@@H](O)C[C@@H](O[C@@H]7OC[C@H](O)[C@H](O)[C@H]7O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@]6(C)[C@H]5CC[C@]4(C)[C@@H]3[C@@H]2C SKHJNNFXCKTDBG-NACOJTGESA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- RZZKWHQUBSTBSP-UHFFFAOYSA-N asparagoside g Chemical compound O1C(CO)C(O)C(O)C(O)C1OCC(C)CCC(C(C1C2(C)CCC3C4(C)CC5)C)(O)OC1CC2C3CCC4CC5OC(C(C1OC2C(C(O)C(O)C(CO)O2)O)O)OC(CO)C1OC1OC(CO)C(O)C(O)C1O RZZKWHQUBSTBSP-UHFFFAOYSA-N 0.000 claims 1
- SXCDJKBVZMMBQG-UHFFFAOYSA-N asparagoside h Chemical compound O1C(CO)C(O)C(O)C(O)C1OCC(C)CCC(C(C1C2(C)CCC3C4(C)CC5)C)(O)OC1CC2C3CCC4CC5OC(C(C1OC2C(C(O)C(O)C(CO)O2)O)O)OC(CO)C1OC(C(C1O)O)OC(CO)C1OC1OCC(O)C(O)C1O SXCDJKBVZMMBQG-UHFFFAOYSA-N 0.000 claims 1
- WSKZQIDNATXNQA-UHFFFAOYSA-N astrasieversianin XIV Natural products CC(C)(O)C1CCC(C)(O1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC6(C)C4(C)CCC23C)OC7OCC(O)C(O)C7O WSKZQIDNATXNQA-UHFFFAOYSA-N 0.000 claims 1
- 229960002376 chymotrypsin Drugs 0.000 claims 1
- RVCBYNPFQBFVTI-UHFFFAOYSA-N cyclosieversioside G Natural products CC1OC(OC2C(O)C(O)COC2OC3CCC45CC46CCC7(C)C(CC(O)C7C8(C)CCC(O8)C(C)(C)O)C6CC(OC9OCC(O)C(O)C9O)C5C3(C)C)C(O)C(O)C1O RVCBYNPFQBFVTI-UHFFFAOYSA-N 0.000 claims 1
- GTFSNPKRIIBFJG-UHFFFAOYSA-N cyclosieversioside H Natural products CC1OC(OC2C(O)C(O)COC2OC3CCC45CC46CCC7(C)C(CC(O)C7C8(C)CCC(O8)C(C)(C)O)C6CC(OC9OC(CO)C(O)C(O)C9O)C5C3(C)C)C(O)C(O)C1O GTFSNPKRIIBFJG-UHFFFAOYSA-N 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- KXUUBVSWDFEXSQ-UHFFFAOYSA-N gitonin Natural products CC1CCC2(OC1)OC3CC4C5CCC6CC(OC7OC(COC8OC(CO)C(O)C(OC9OCC(O)C(O)C9O)C8OC%10OC(CO)C(O)C(O)C%10O)C(O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C KXUUBVSWDFEXSQ-UHFFFAOYSA-N 0.000 claims 1
- 229940116332 glucose oxidase Drugs 0.000 claims 1
- 235000019420 glucose oxidase Nutrition 0.000 claims 1
- SYXUBXTYGFJFEH-UHFFFAOYSA-N oat triterpenoid saponin Chemical compound CNC1=CC=CC=C1C(=O)OC1C(C=O)(C)CC2C3(C(O3)CC3C4(CCC5C(C)(CO)C(OC6C(C(O)C(OC7C(C(O)C(O)C(CO)O7)O)CO6)OC6C(C(O)C(O)C(CO)O6)O)CCC53C)C)C4(C)CC(O)C2(C)C1 SYXUBXTYGFJFEH-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- LVTJOONKWUXEFR-UEZXSUPNSA-N protodioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@@H]5O[C@]([C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)(O)CC[C@@H](C)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O LVTJOONKWUXEFR-UEZXSUPNSA-N 0.000 claims 1
- MHKGPHKABOLURA-JNVLQWCMSA-N protodioscin Natural products C[C@@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O[C@H]4CC[C@]5(C)[C@H]6CC[C@@]7(C)[C@@H](C[C@@H]8O[C@](O)(CCCCO[C@@H]9O[C@H](CO)[C@@H](O)[C@H](O)[C@H]9O)[C@@H](C)[C@H]78)[C@@H]6CC=C5C4)O[C@@H]2CO)[C@H](O)[C@H](O)[C@H]1O MHKGPHKABOLURA-JNVLQWCMSA-N 0.000 claims 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims 1
- BKSZALUUQJKDOV-BRYDKAIJSA-N protoyuccoside h Chemical compound O([C@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O[C@@H]1[C@@H]([C@@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1)O)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@H]2CCC3C4CC5O[C@]([C@H](C5[C@@]4(C)CCC3[C@@]2(C)CC1)C)(O)CC[C@@H](C)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O BKSZALUUQJKDOV-BRYDKAIJSA-N 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229930002534 steroid glycoside Natural products 0.000 abstract description 8
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 abstract description 3
- 230000002209 hydrophobic effect Effects 0.000 abstract description 3
- 239000002459 polyene antibiotic agent Substances 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 37
- 239000000243 solution Substances 0.000 description 31
- 201000001320 Atherosclerosis Diseases 0.000 description 17
- 238000003745 diagnosis Methods 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000012467 final product Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000000472 traumatic effect Effects 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 150000003141 primary amines Chemical class 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 150000002118 epoxides Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000007390 skin biopsy Methods 0.000 description 3
- ZRLNBWWGLOPJIC-PYQRSULMSA-N A'-neogammacerane Chemical compound C([C@]1(C)[C@H]2CC[C@H]34)CCC(C)(C)[C@@H]1CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@@H]1C(C)C ZRLNBWWGLOPJIC-PYQRSULMSA-N 0.000 description 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010020852 Hypertonia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000007981 phosphate-citrate buffer Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000003966 vascular damage Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YFESOSRPNPYODN-RSMWSHJLSA-N (2s,3s,4s,5r,6r)-6-[[(4s,6ar,6bs,8r,8ar,9r,10r,14br)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2s,3r,4s, Chemical compound O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(/C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YFESOSRPNPYODN-RSMWSHJLSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- CFYIUBWVKZQDOG-UHFFFAOYSA-N 4-[[2-[[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-oxobutanoic acid Chemical compound C=1C=C([N+]([O-])=O)C=CC=1NC(=O)C(NC(=O)CNC(=O)CNC(=O)CCC(=O)O)CC1=CC=CC=C1 CFYIUBWVKZQDOG-UHFFFAOYSA-N 0.000 description 1
- BQNMOLSYHYSCMS-UHFFFAOYSA-N 5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-10',16'-diol Chemical compound CC1C(C2(C(O)CC3C4(C)CCC(O)CC4CCC3C2C2)C)C2OC11CCC(C)CO1 BQNMOLSYHYSCMS-UHFFFAOYSA-N 0.000 description 1
- ZBFDAUIVDSSISP-UHFFFAOYSA-N 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine Chemical compound N=1C2=NC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C ZBFDAUIVDSSISP-UHFFFAOYSA-N 0.000 description 1
- YEKZYRCPUZIPAI-UHFFFAOYSA-N Agavoside B Natural products O1C2(OCC(C)CC2)C(C)C(C2(C(=O)CC3C4(C)CC5)C)C1CC2C3CCC4CC5OC(C(C1O)O)OC(CO)C1OC1OC(CO)C(O)C(O)C1O YEKZYRCPUZIPAI-UHFFFAOYSA-N 0.000 description 1
- YEKZYRCPUZIPAI-IEBUPIFISA-N Agavoside B Chemical compound O([C@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(C(=O)C[C@@H]3[C@@]2(C)CC1)C)[C@@H](C1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YEKZYRCPUZIPAI-IEBUPIFISA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100035687 Bile salt-activated lipase Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101000597253 Clostridium novyi Phospholipase C Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 244000182691 Echinochloa frumentacea Species 0.000 description 1
- 235000008247 Echinochloa frumentacea Nutrition 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010020056 Hydrogenase Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- GMBQZIIUCVWOCD-UQHLGXRBSA-N Isosarsasapogenin Natural products O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 GMBQZIIUCVWOCD-UQHLGXRBSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710103914 Perfringolysin O Proteins 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 229940122605 Short-acting muscarinic antagonist Drugs 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229930185631 capsicoside Natural products 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- SIGPWCVHTYIKME-UHFFFAOYSA-N hexamethanol Chemical compound OC.OC.OC.OC.OC.OC SIGPWCVHTYIKME-UHFFFAOYSA-N 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- PYVSHVUPVKOSBE-UHFFFAOYSA-N purpureagitoside Natural products O1C(CO)C(O)C(O)C(O)C1OCC(C)CCC(C(C1C2(C)CCC3C4(C)CC5O)C)(O)OC1CC2C3CCC4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O PYVSHVUPVKOSBE-UHFFFAOYSA-N 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 108010075210 streptolysin O Proteins 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (5)
- PŘEDMĚT VYNÁLEZU1. Způsob přípravy afinně enzymatických sloučenin pro vizuální indikaci cholesterolu na povrchu kůže pacienta na bázi detekčniho činidla a vizualizačniho činidla, vyznačující se tím, že se afinní detekční činidlo A zvolené ze skupiny, která zahrnuje steroidni glykoeidy majici ve svém složeni jako aglykon cyklopentanporhydrofenantrenový zbytek furostanolové nebo spirostanolové řady a oligoeacharidový fragment obsahující 3 až 10CS 274 504 B2 monosacharidů přímé nebo rozvětveně řady, ze skupiny zahrnující agavosid A, agavosid 13, agavosid C, agavosid O, agavosid F, agavosid H, agavosid G, trillin, funcosid C, funcosid 0, funcosid F, funcosid G, funcosid I, dioscin, gracillin, protodioscin, cícubasaponin, juncosid E, juncosid H, lanatigonin, desglukodigitonin, digitonin, gitonin, rocosid C, rocosid 0, rocosid E, funcosid E, alliumosid C, polygonatonin, tigogenintetraosid, tigogeninhexaosid, capsicosld, ammunosid B, ammunosid C, ammunosid D, ammunosid E, desglukodesramnoparillin, desglukoparillin, parillin, sarsaparillosid, asparagosid C, asparagosid 0, asparagosid G, asparagosid H, protoyuccosid H, yuokkosid B, lanatigosid, monosid, biosid, triosid, purpuraagitosid, gekogenin, rocogenin, diogenin, tigogenin, protopolygametosid, tomatonin, laxogeninlycotetraosid, alliogeninlycoteraosid, karoteosid A, cyclosieversiosid H, acantofilosid C, alliofusosid A, alliospirosid A, cyklosieversiosid F, theasaponin, ačantofilosid B, tigonin (celkový), glykosid rostliny Calha polypetala nebo cyclosieversiosid G, nebo ze skupiny triterpenglykosidů, obsahující agylkon o(- nebo β-amyrylové, lupanové, hopanové, damaranové, lanostanové nebo holostanové řády a oligosacharid sa 2 až B rozvětvenými nebo nerozvětvenými zbytky, zahrnující následujici soubor látek - aescin, avenacin, theasaponin, Ct-hederin, caulosid C, stichinosid A, cyclamin, chinovin, saponiny cukrové řepy, hypsosid i tritsrpenglykosidy ziskané z rostliny Fatsia japonica, detekční činidlo A je dále voleno ze skupiny hydrofobnich bílkovin, kterými jsou meilinové bílkoviny podls Folcha, bílkoviny lysozomů a mitochondrii, fibrinogen, immunoglobuliny, cerebron, myoglobin, cytochrom C, cytochrom P-450 nebo apoproteiny lipoproteinů, ze skupiny bilkovinových toxinů schopných tvořit komplexní sloučeninu s cholesterolem, které lze získat z bakterii, mořských mikroorganismů, hmyzu a hadů, která zahrnuje streptolysin o, pneumolysin, listeriolysin, #-toxin C.X. získaný z Psrfringens typu A a C, cf—t oxin C.I. nový typ A a C, haemolysin C.I. histolyticum, haemolysin C.I. botulinum typ C a D, tetanolysin, cerebroíysin, alveolysin, tíiringeolysin nsbo cytotoxin z aktinie Metridium senile, ze skupiny polyenantibiotik zahrnujici amphotericin B, philipin nabo nistatin, ze skupiny enzymů, majících vysokou afinitu k cholesterolu, zahrnujici cholesteroloxidazy, cholssterolhydrogsnázy nebo cholesterolesterázy, a vizualizační činidlo B, vybrané ze souboru, který tvoři enzymy acetylcholinesteráza, tyrosinázy, glukoso-6-fosfátdehydrogenázy, glukooxidáza, glukoeoamyláza, galaktosidáza, peroxidáza, alkalické nebo kyselé fosfatázy,té-chymotrypsin nebo pyrofosfatáza, necháji reagovat se zesitovacim činidlem C, vybraným zs skupiny, kterou tvoři nízkomolekulární bifunkční sloučeniny, zahrnující bromkyan, trichlortriazin nebo 2-amino-4,S-dichlor-3-triazin, nebo vysokomolekulární sloučeniny, obsahujíc! jakoukoliv z funkčních skupin zvolených ze souboru, který zahrnuje primární aminoskupinu, karboxyl, hydroxyl, aldehydovou skupinu, hydrohalogenidovou skupinu, skupinu smíšeného anhydridu, lminoetherovou skupinu, azidovou skupinu, hydrazidovou skupinu, maleiimidovou, isokyanátovou nebo epoxidovou skupinu, nechají reagovat ve vodném solném tlumivém roztoku o hodnotě pH 5 až 9 při toplotě O až 20 °C, přičemž se roakco provádi v libovolném pořadí.'2. Způsob podle bodu 1, vyznačující se tim, že afinní detekční činidlo uvedené v bodě 1 rozpustí ve vodném solném tlumivém roztoku o hodnotě pH 5 až 9 v koncentraci od 1 do 20 mg/ml a roztok se nechá reagovat s nizkomolekulárnim asymetrickým bifunkčnim zesitovacim činidlem C zvoleným ze souboru, který zahrnuje bromkyan, trichlortriazin nebo
- 2-amino-4,G-dichlor-S-triazin v molárnim poměru AsC o 1:0,5 až 1:10 a roztok se udržuje 1 až 20 hodin při teplotě od O do 20 °C, pak se přidá vizualizační činidlo B zvolené ze souboru enzymů, který zahrnuje acetylcholinesterázu, tyrosinázu, glukoso-6-fosfátdehydrogenázu, glukosooxidázu, glukosoamylázu, galaktosidázu, peroxidázu, alkalickou nebo kyselou fosfatázii, (X- alkalickou nebo kyselou fosfatázu,0(- chymotrypsin neboCS 274 504 B2 pyrofosfatázu, v molárnim poměru A:B a 20:1 až 1:1 a roztok se 1 až 48 hodin udržuje při teplotě O až 20 °C.
- 3. Způsob podle bodu 1, vyznačujici se tim, že se vizualizačni činidlo B, zvolené ze skupiny enzymů, zahrnující acetylcholinesterázu, tyrosinázu, glukoso-6-fosfátdehydrogenázu, glukosooxidázu, glukosoamylázu, gelaktosidázu, peroxidázu, alkalickou nebo kyselou fosfatázu, OC-chymotrypsin nebo pyrofosfatázu, rozpustí ve vodném solném tlumivém roztoku o pH 5 až 9 při koncentraci vizualizačniho činidla B 1 až 20 mg/ml, přidá se nizkomolekulární asymetrické zesitovaci činidlo C, vybrané ze skupiny zahrnující bromkyan, trichlortriazin nebo 2-amino-4,6-dichlor-S-triazin v molekulárním poměru B:C a 1,0:0,5 až 1:10 a roztok ee udržuje 1 až 20 hodin ha teplotě O až 20 °C a pak se nechá reagovat s detekčnim činidlem A, majícim význam uvedený v bodě 1, v molárnim poměru A:B e 20:1 až 1:1 a roztok se udržujo 1 až 48 hodin při teplotě O až 20 °C.
- 4. Způsob podle bodu 1, vyznačující se tim, že se detekční činidlo A, majici význam uvedený v bodě 1, nebo směs těchto látek, spolu s vizualizačnim činidlem B, zvoleným ze skupiny enzymů, zahrnující acetylcholinesterázu, tyrosinázu, glukoso-5-fosfátdehydrogenázu, glukosooxidázu, glukosoamylázu, galaktosidázu, peroxidázu, alkalickou nebo kyselou fosfatázu nebo 'X-chymotryp3in, rozpustí v molárnim poměru A:B = 20:1 až 1:1 ve vodném solném tlumivém roztoku o hodnotě pH 5 až 9 při koncentraci A a B vždy 0,1 až 20 mg/ml, získaný roztok se nechá reagovat s vysokoroolekulárnim polyfunkčním zesitovacim činidlem C, kterým jsou polysacharidy, proteiny nebo syntetické polymery, obsahující jakoukoliv z funkčních skupin, zahrnující primární aminovou karboxylovou, hydroxylovou, aldehydovou, hydrohalogenidovou skupinu, skupinu smíšeného anhydridu, azidovou, hydrazidovou, maleimidovou, isokyanátovou nebo epoxidovou skupinu, nechá reagovat v molárnim poměru (A+B) :C = 1:0,5 až 1:10 a získaný roztok se udržuje 1 až 20 hodin při teplotě O. až 20 °C.
- 5. Způsob podle lo C použijeZpůsob podle lo C použije bodu 4, vyznačujici se tim, že se jako vysokomolekulárni zesitovaci činidkopolymer akrylové kyseliny nebo anhydridu kyseliny maleinové.bodu 5, vyznačujici se tim, že se jako vysokomolekulárni zesitovaci činidkopolymer N-vinylpyrrolidonu a anhydridu kyseliny maleinové.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS503989A CS274504B2 (en) | 1988-01-19 | 1989-08-30 | Preparation of enzymatic compounds for cholesterol optical indication |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU884357046A SU1675769A1 (ru) | 1988-01-19 | 1988-01-19 | Способ получени средства дл визуальной индикации холестерина на поверхности кожи |
| CS34889A CS274496B2 (en) | 1988-01-19 | 1989-01-18 | Method of affinitive-enzymatic compounds preparation for cholesterol's visul indication |
| CS503989A CS274504B2 (en) | 1988-01-19 | 1989-08-30 | Preparation of enzymatic compounds for cholesterol optical indication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CS503989A2 CS503989A2 (en) | 1990-08-14 |
| CS274504B2 true CS274504B2 (en) | 1991-04-11 |
Family
ID=25745276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS503989A CS274504B2 (en) | 1988-01-19 | 1989-08-30 | Preparation of enzymatic compounds for cholesterol optical indication |
Country Status (1)
| Country | Link |
|---|---|
| CS (1) | CS274504B2 (cs) |
-
1989
- 1989-08-30 CS CS503989A patent/CS274504B2/cs unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CS503989A2 (en) | 1990-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dahlqvist | A method for the determination of amylase in intestinal content | |
| US4333734A (en) | Diagnostic device for fecal occult blood and method of use | |
| Herriott | Acetylation of tyrosine in pepsin | |
| Hino et al. | Glycylprolyl β-naphthylamidase activity in human serum | |
| US5587295A (en) | Method for producing affino-enzymatic compounds and visualizing agent and application thereof | |
| US3235337A (en) | Diagnostic compositions and test indicators | |
| Porembska et al. | Early diagnosis of myocardial infarction by arginase activity determination | |
| CS274496B2 (en) | Method of affinitive-enzymatic compounds preparation for cholesterol's visul indication | |
| Belfiore et al. | Increased activity of some enzymes in serum in cases of severely decompensated diabetes, with and without ketoacidosis | |
| Kim et al. | β-Glucuronidase studies in gastric secretions from patients with gastric cancer | |
| Hill et al. | Probable genetic linkage between human serum amylase (Amy 2) and Duffy blood group | |
| RU2009509C1 (ru) | Способ прогнозирования течения псориаза | |
| CS274504B2 (en) | Preparation of enzymatic compounds for cholesterol optical indication | |
| EP1376133A1 (en) | Method of screening prediabetic state and screening reagent | |
| Ziegler et al. | Oxidative metabolism of tertiary amine drugs by human liver tissue | |
| Weaver et al. | Aged amylase: a valuable test for detecting and tracking pancreatic pseudocysts | |
| Lojda et al. | Histochemical demonstration of the intestinal hetero-β-galactosidase (glucosidase) | |
| NL8901732A (nl) | Werkwijze voor het bereiden van affino-enzymatische verbindingen voor visuele aanduiding van cholesterol op huidoppervlak gebaseerd op een detecterend middel met affiniteit voor cholesterol en visualiserend middel en toepassing daarvan. | |
| Hospattankar et al. | Elevation of serum polyamines in malignant lymphomas and acute myeloid leukemia | |
| Lijnen et al. | Biological significance of active and inactive renin in man | |
| CN117701674B (zh) | 抗黄芩素干扰的高密度脂蛋白胆固醇检测试剂盒及其应用 | |
| US3715188A (en) | Cholesterol assay and reagents therefor | |
| FLESCH et al. | Further studies of epidermal mucopolysaccharides | |
| JPS592700A (ja) | 総ポリアミンの測定方法 | |
| Lundquist et al. | Fine-needle Aspiration Biopsy of the Liver in Healthy Adults Activity of Lysosomal Acid Hydrolases |